focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Retail Offer

7 Jul 2020 17:46

RNS Number : 3125S
e-Therapeutics plc
07 July 2020
 

EMBARGOED FOR ON 7 JULY 2020.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014.

THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF E-THERAPEUTICS PLC.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT (EACH A "RESTRICTED JURISDICTION").

THIS ANNOUNCEMENT AMOUNTS TO A FINANCIAL PROMOTION FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 ("FSMA") AND HAS BEEN APPROVED BY PRIMARYBID LIMITED WHICH IS AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY (FRN 779021)

 

7 July 2020

 

e-therapeutics plc

 

("e-therapeutics" or the "Company")

 

Retail Offer

 

e-therapeutics plc (AIM: ETX.L) is pleased to announce a conditional offer for subscription via PrimaryBid (the "Retail Offer") of new ordinary shares of 0.1p each in the Company ("Retail Shares") at an issue price of 12 pence per New Ordinary Share (the "Issue Price"), being a discount of 30.9 per cent to the closing mid-price of 17.4 pence per New Ordinary Share on 6 July 2020, being the latest practicable date prior to the time and date of this announcement.

The Company is also conducting a placing of new Ordinary Shares at the Issue Price by way of a firm placing by Numis Securities Limited (the "Firm Placing"), an associated broker option in the event of additional demand (the "Broker Option"), and direct subscriptions with the Company by individual investors based in various overseas jurisdictions (the "Subscription"), as announced on 7 July 2020.

The PrimaryBid Offer, the Subscription and the Firm Placing are conditional on the new Ordinary Shares to be issued pursuant thereto being admitted to trading on the AIM market of the London Stock Exchange ("Admission"). Admission is expected to be take place at 8.00 a.m. on 15 July 2020. The Retail Offer will not be completed without the Firm Placing also being completed.

The Company will use the funds raised to facilitate a number of initiatives to enable the Company's next stage of growth and value creation by expanding the Company's platform capabilities and asset pipeline.

 

Retail Offer

The Company values its retail investor base and is therefore pleased to provide private and other investors the opportunity to participate in the Retail Offer by applying exclusively through the www.PrimaryBid.com platform and the PrimaryBid mobile app available on the Apple App Store and Google Play.

The Retail Offer, via the PrimaryBid.com platform, will be open to individual and institutional investors from 4.45 p.m. to 9 p.m. on 7 July 2020. The Retail Offer may close early if it is oversubscribed.

Subscriptions under the Retail Offer will be considered by the Company on a "first come, first served" basis, although preference to be given to the Company's existing shareholders, subject to conditions which are available to view on PrimaryBid.com.

The Company in consultation with PrimaryBid reserves the right to scale back any order at its discretion. The Company and PrimaryBid reserve the right to reject any application for subscription under the Retail Offer without giving any reason for such rejection.

No commission is charged to investors on applications to participate in the Retail Offer made through PrimaryBid. It is vital to note that once an application for Retail Shares has been made and accepted via PrimaryBid, an application cannot be withdrawn.

For further information on PrimaryBid.com or the procedure for applications under the Retail Offer, visit www.PrimaryBid.com or call PrimaryBid.com on +44 20 3026 4750. 

The Retail Shares will be issued free of all liens, charges and encumbrances and will, when issued and fully paid, rank pari passu in all respects with the Company's existing Ordinary Shares.

e-therapeutics plc

Ali Mortazavi, Executive Chairman

Laura Roca-Alonso, Chief Business Officer

 

 

+44 (0)1993 883 125

www.etherapeutics.co.uk

PrimaryBid Limited

Kieran D'Silva / James Deal

+ 44 (0) 203 026 4750

 

 

FTI Consulting

Simon Conway/Stephanie Cuthbert

 

 

 

+44 (0) 203 727 1000

e-therapeutics@fticonsulting.com

Details of the Retail Offer

The Company values its retail investor base which has supported the Company alongside institutional investors over several years. Given the longstanding support of retail shareholders, the Company believes that it is appropriate to provide retail and other interested investors the opportunity to participate in the Retail Offer. The Company is therefore offering the Retail Shares through PrimaryBid.com.

The Retail Offer is being made pursuant to an exemption from the requirement to publish a prospectus allowed under the Prospectus Rules. As such, there is no need for publication of a prospectus pursuant to the Prospectus Rules, or for approval of the same by the Financial Conduct Authority. The Retail Offer is not being made into any Restricted Jurisdiction.

There is a minimum subscription of £100 per investor under the terms of the Retail Offer which is open to existing shareholders and other investors subscribing via PrimaryBid.com. This allocation will be filled on a "first come first served" basis, although preference will be given to existing shareholders.

For further details please refer to the PrimaryBid.com website at www.PrimaryBid.com. The terms and conditions on which the Retail Offer is made, including the procedure for application and payment for Retail Shares, is available to all persons who register with PrimaryBid.com.

Investors should make their own investigations into the merits of an investment in the Company. Nothing in this announcement amounts to a recommendation to invest in the Company or amounts to investment, taxation or legal advice.

It should be noted that a subscription for Retail Shares and investment in the Company carries a number of risks. Investors should consider the risk factors set out on PrimaryBid.com before making a decision to subscribe for Retail Shares. Investors should take independent advice from a person experienced in advising on investment in securities such as the Retail Shares if they are in any doubt. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

 

END

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOERRMFTMTJMBLM
Date   Source Headline
24th May 20116:30 pmRNSDirector/PDMR Shareholding
23rd May 20115:59 pmRNSDirector/PDMR Shareholding
15th Mar 20112:47 pmRNSDirector/PDMR Shareholding
15th Mar 201110:35 amRNSHolding(s) in Company
14th Mar 201112:00 pmRNSDirector/PDMR Shareholding
10th Mar 201111:07 amRNSRe-statement of Directors' Interests
10th Mar 201110:20 amRNSHolding(s) in Company
8th Mar 20116:11 pmRNSHolding(s) in Company
8th Mar 20116:01 pmRNSHolding(s) in Company
7th Mar 20118:22 amRNSCompletion of the Placings
4th Mar 20119:13 amRNSDirector/PDMR Shareholding
3rd Mar 20112:08 pmRNSResult of General Meeting
2nd Mar 20119:28 amRNSDirector/PDMR Shareholding
15th Feb 20117:30 amRNSIssue of Equity
3rd Feb 201112:09 pmRNSIssue of Equity
6th Dec 20107:00 amRNSDirectorate Change
29th Oct 20107:00 amRNSe-Therapeutics plc Interim Results
22nd Sep 20107:00 amRNSComprehensive Set of Patents Granted in US
8th Sep 201010:24 amRNSAGM Statement
30th Jul 20108:00 amRNSAnnual Financial Report
29th Jul 201010:23 amRNSAdditional Listing
2nd Jul 20108:00 amRNSDirectors' Interests
29th Jun 20107:00 amRNSFinal Results
25th May 20107:30 amRNSChange of Adviser
29th Apr 20109:02 amRNSIssue of Equity
29th Apr 20107:00 amRNSPre-close operational update and notice of Results
10th Mar 20104:01 pmRNSDirector's interest
2nd Mar 20109:30 amRNSDirector's shareholdings
15th Feb 20107:00 amRNSContract for iGCP trials with Infinitus
11th Nov 20095:46 pmRNSHolding(s) in Company
2nd Nov 200912:00 pmRNSPlacing
30th Oct 20097:00 amRNSInterim results
2nd Sep 200910:05 amRNSResult of AGM
11th Aug 20097:00 amRNSNotice of AGM
27th Jul 20097:42 amRNSPreliminary Results
14th Jul 20097:00 amRNSNotice of Results
25th Jun 20091:00 pmRNSChange of Adviser
17th Jun 20094:05 pmRNSDirector/PDMR Shareholding
9th Jun 200911:36 amRNSDirector Declaration
16th Mar 20094:34 pmRNSResult of General Meeting
11th Mar 20092:19 pmRNSDirector/PDMR Shareholding
25th Feb 20093:00 pmRNSNotice of General Meeting
25th Feb 20097:00 amRNSConditional Investment & Notice of General Meeting
24th Feb 20097:00 amRNSRevenue share agreement with Khandelwal
26th Jan 20097:00 amRNSStrategic Partnership
14th Jan 20097:00 amRNSPositive Phase IIa results for antidepressant
12th Jan 20091:23 pmRNSUS patent granted
12th Nov 20085:04 pmRNSShare Option Award
11th Nov 20083:02 pmRNSGrant of patents
31st Oct 20087:00 amRNSDirector's Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.